Lorcaserin, Arena Pharmaceutical's (Nasdaq:ARNA) experimental obesity drug, was not necessarily the last best hope for new obesity medications, but a 5-9 panel vote against recommending FDA approval is a pretty clear indication that the standards for obesity drugs are exceptionally high. This ruling is not altogether shocking in the wake of Vivus' (Nasdaq: VVUS) similar rejection on Qnexa, but it should certainly have Orexigen (Nasdaq:OREX) shareholders feeling nervous when their company's number comes up.

IN PICTURES: 8 Ways To Survive A Market Downturn

Why The Panel Said "No"
It was clear from listening to the proceedings that many panelists had issues with the efficacy and safety of the drug, as well as how Arena went about designing the trials and performing the statistical analysis. If I may be so bold, though, it sounded like at least a few panel members went in locked and loaded with a mindset against this drug and judging by their comments and concerns, it is difficult to foresee just how good a drug would have to be to get their blessing. (For more, see Arena's Big Day Looms Large.)

Frankly, the efficacy concerns seem legitimate. An average weight loss of 5.8% is not all that special and when factoring in the placebo effect it was only a 3.7% net benefit - below the FDA's stated standard. On the other hand, an argument can be made that almost any weight loss is beneficial and nearly half of people taking lorcaserin (47.5%) lost 5% or more of their starting weight (versus 20% of placebo patients). So, in a nutshell, lorcaserin helps a bit, but not a lot.

The Safety Bugaboo
Safety concerns seem to be what really spooked the panelists. There was a lot of quibbling about whether Arena's data supported the idea that lorcaserin did not increase the risk of valvulopathy (a severe side-effect that doomed an obesity drug marketed by Wyeth, now part of Pfizer (NYSE:PFE)). (Learn more in 5 Warning Signs For Bad PR Stocks.)

While Arena's data certainly looked clean, it almost appeared that the panelists wanted the impossible - for Arena to prove that lorcaserin could not/would not/did not cause this condition, and proving a negative is exceptionally difficult.

Beyond that, the risk of cancer (especially breast cancer) came up more than once. Disappointed Arena bulls may fume that the panelists were obsessing about trends seen in rats given ridiculously high doses of the drug, but the reality is that that is how these studies are generally done and panelists are always worried about cancer risks in drugs likely to be taken for long periods of time. (For more, see Can Investors Fatten Up On Weight Loss?)

Where To From Here?
Arena's stock responded quite badly to this news, but it certainly bears mention that Arena is not necessarily doomed. The FDA does not have to follow the advice of this panel. The FDA could choose to approve the drug or re-examine it again when the company has more data (the company is currently in progress with a study of lorcaserin in diabetics). Still, this is a company no other shots on goal for many years, and an uncomfortable net-cash position.

For Orexigen, this is definitely a warning shot. I felt that Arena's drug had arguably the best risk-reward trade-off, so Orexigen could have a heck of a time convincing the panelists to recommend approval of a drug with some pretty concerning side-effects. On the other hand, if Orexigen somehow makes it, the market could be all theirs (and their partner Takeda's) and a middling drug with competition could do well with the whole market to itself. (For more, see Orexigen Finds A Cautious Partner.)

The Bottom Line
In the meantime, the message from the FDA to people struggling with obesity seems to be "you are on your own". It is all well and good for the FDA to make sure potential new drugs are safe (that is its job and its mandate), but going overboard and setting a bar that no one can reach helps no one in the long run.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Time to Bring Active Back into a Portfolio?

    While stocks have rallied since the economic recovery in 2009, many active portfolio managers have struggled to deliver investor returns in excess.
  2. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  3. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  4. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  5. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  6. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  7. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  8. Investing

    What’s the Difference Between Duration & Maturity?

    We look at the meaning of two terms that often get confused, duration and maturity, to set the record straight.
  9. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  10. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center